Last reviewed · How we verify

NCT03494400: ATTBC

Aerobic Training in Treatment for Breast Cancer

Completed NA Last updated 30 April 2021
What this trial tests

NA trial testing Aerobic Training Presential in Cancer of Breast in 6 participants. Completed in 30 November 2020.

Timeline
1 July 2018
Primary endpoint
23 June 2019
30 November 2020

Quick facts

Lead sponsorUniversidade Estadual Paulista Júlio de Mesquita Filho
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment6
Start date1 July 2018
Primary completion23 June 2019
Estimated completion30 November 2020
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Universidade Estadual Paulista Júlio de Mesquita Filho — full company profile →

Who can join

18 and older, female only, with Cancer of Breast or Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction. Treatment with hormone therapy reduced the likelihood of tumor recurrence and metastasis in the patient. However, it has adverse effects such as: loss of bone mineral density, increase in body weight, metabolic changes and, consequently, lower quality of life. Physical training has been used as a means of reducing these and other adverse effects, but there is no definite protocol on which training model is effective, especially in patients who only use Tamoxifen or Aromatase Inhibitor as an adjuvant therapy for treatment of breast cancer. Objective: To compare the effect of aerobic training on body composition, metabolic and inflammatory variables, physical activity level, sleep, anxiety, depression, body image, fatigue, strength, flexibility and quality of life of women undergoing breast cancer treatment use Tamoxifen and Aromatase Inhibitor and women without cancer. Method. The sample will be formed by women without cancer and under treatment with hormone therapy being accompanied by the public service for treatment of breast cancer of the city of Presidente Prudente. A 24-week notification in which the face-to-face training group will undergo aerobic training three times a week on interspersed days and the group accompanied at a distance will perform as a preferred activity under a distance supervision of professionals every 14 days of return to attend the UNESP for the adequacy of the analysis and selection of attendance to the proposed activities. Evaluations of the variables of interest at the baseline of the intervention will be performed after 12 weeks and soon after the intervention. The investigators will analyze: biomarkers (TNFα, LDL, HDL, VLDL, as well as in the lipid profile (triglycerides, total cholesterol and LDL fractions ), glycemia, insulin, anthropometric measurements, physical activity level, sleep, pain, anxiety, depression, body image, fatigue, strength, flexibility. Trainings will be performed within the target zone of maximum heart rate. Comparisons between groups at each time point will be performed using Student's T-test for independent samples. The comparisons of the variables of interest at the initial moment and after 12 and 24 weeks will be made through the multivariate analysis, where the group effects, time and interaction of both will be compared. All analyzes will be performed in SPSS software version 24.0 and significance of 5%.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Impact of home-based aerobic training combined with food orientation on food consumption, daily physical activity and cardiorespiratory fitness among breast cancer survivors: six-month clinical trial.
    Reis AD, Lima LS, Barros ÊADC, Bertoli J, et al · · 2021 · cited 1× · PMID 33978132 · DOI 10.1590/1516-3180.2020.0658.28012021

Verify or expand the search:

Other recruiting trials for Cancer of Breast

Currently open trials in the same condition.

Other Universidade Estadual Paulista Júlio de Mesquita Filho trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03494400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing